Deadline: 27-Dec-24
The Pfizer Research Grant aims to support preclinical research in hemophilia that investigate strategies to evaluate hemostatic potential of anti-TFPI therapies.
Funding Information
- Individual projects requesting up to $50,000 USD will be considered. Pfizer anticipates awarding 2-4 projects in total.
Duration
- Anticipated project length is 12 months.
Geographic Scope
- US, Europe, Japan, China, Brazil and Saudi Arabia
Eligible Projects and Area of Interest
- Eligible projects will be considered for financial/non-financial support and will prioritize independent preclinical research aimed at enhancing the medical and scientific understanding of hemostasis in the setting of TFPI inhibition in hemophilia.
- Grant requests for drug/compound only are also in scope of this RFP.
- The results of these studies will help prepare clinicians and laboratory specialists for the integration of novel hemophilia therapies into local standard treatment protocols.
Eligibility Criteria
- The institution and Principal Investigator (PI) must be based in one of the eligible countries.
- Only organizations are eligible to receive grants, not individuals or medical practice groups (i.e., an independent group of physicians not affiliated with a hospital, academic institution, or professional society).
- If the project involves multiple departments within an institution and/or between different institutions / organizations / associations, all institutions must have a relevant role and the requesting organization must have a key role in the project.
- The PI must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.
- The applicant must be the PI or an authorized designee of such individual (e.g., PI’s research coordinator).
- The PI must be an employee or contractor of the requesting organization.
For more information, visit Pfizer.